eFFECTOR Therapeutics, Inc.
EFTRDelisted Jul 19, 2024- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001828522
eFFECTOR Therapeutics, Inc. was delisted on Jul 19, 2024; its insiders filed their last Form 4 on Jun 13, 2024; 18 institutions reported holding it in 13F filings for Q2 2024, worth $251.1K in total; no superinvestor held it.
13F holders, Q2 2024
Institutional positions in eFFECTOR Therapeutics, Inc. as of Jun 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
EFTR is no longer listed, so this page shows Q2 2024. 13F filings for later quarters list far fewer holders.
- Institutional holders
- 18
- +1 vs. Q1 2024
- Shares held
- 868.0K
- −70.8K (−7.5%) vs. Q1 2024
- Total value
- $251.1K
- −$13.2M (−98.1%) vs. Q1 2024
- New holders
- 8
- 3 more added
- Sold out
- 7
- 2 more reduced
Compare with Q1 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting EFTR on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 1 | $0 |
| Q1 2026 | 1 | $0 |
| Q4 2025 | 1 | $0 |
| Q3 2025 | 1 | $0 |
| Q2 2025 | 1 | $0 |
| Q1 2025 | 1 | $0 |
| Q4 2024 | 0 | $0 |
| Q3 2024 | 3 | $4.33K |
| Q2 2024 | 18 | $251.1K |
| Q1 2024 | 17 | $13.5M |
| Q4 2023 | 24 | $5.44M |
| Q3 2023 | 29 | $14.0M |
| Q2 2023 | 33 | $20.2M |
| Q1 2023 | 26 | $8.29M |
| Q4 2022 | 30 | $10.4M |
| Q3 2022 | 27 | $13.7M |
| Q2 2022 | 24 | $33.9M |
| Q1 2022 | 19 | $89.7M |
| Q4 2021 | 18 | $174.2M |
| Q3 2021 | 12 | $187.9M |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2024
Shares, value and share of portfolio for each institution holding eFFECTOR Therapeutics, Inc.; share changes are against Q1 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Royal Bank of Canada | 546 | $0 | 0.00% | +114+26.4% | Added |
| Qube Research & Technologies Ltd | 3 | $1 | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 31 | $9 | 0.00% | +31 | New |
| Barclays PLC | 100 | $29 | 0.00% | +100 | New |
| Morgan Stanley | 240 | $70 | 0.00% | −1,375−85.1% | Reduced |
| Tower Research Capital LLC (TRC) | 9,805 | $2.84K | 0.00% | +8,271+539.2% | Added |
| Sea Otter Advisors LLC | 10,557 | $3.06K | 0.03% | 00.0% | Unchanged |
| Two Sigma Investments, LP | 11,115 | $3.22K | 0.00% | +11,115 | New |
| Virtu Financial LLC | 18,021 | $5.00K | 0.00% | +18,021 | New |
| Jane Street Group, LLC | 18,669 | $5.42K | 0.00% | +18,669 | New |
| HRT Financial LP | 21,528 | $6.00K | 0.00% | +21,528 | New |
| Vanguard Group Inc | 25,070 | $7.27K | 0.00% | −67,395−72.9% | Reduced |
| Geode Capital Management, LLC | 25,583 | $7.42K | 0.00% | +2,974+13.2% | Added |
| Blackstone Group Inc. | 52,343 | $15.2K | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 61,667 | $17.9K | 0.00% | +61,667 | New |
| Parallel Advisors, LLC | 67,738 | $19.7K | 0.00% | 00.0% | Unchanged |
| Carlyle Group Inc. | 192,884 | $55.9K | 0.01% | 00.0% | Unchanged |
| Sabby Management, LLC | 352,084 | $102.1K | 1.36% | +352,084 | New |
| Armistice Capital, LLC | 0 | $0 | 0.00% | −223,000−100.0% | Sold out |
| StemPoint Capital LP | 0 | $0 | 0.00% | −132,793−100.0% | Sold out |
| Sectoral Asset Management Inc | 0 | $0 | 0.00% | −95,305−100.0% | Sold out |
| Ensign Peak Advisors, Inc | 0 | $0 | 0.00% | −32,945−100.0% | Sold out |
| Raymond James & Associates | 0 | $0 | 0.00% | −12,345−100.0% | Sold out |
| ICA Group Wealth Management, LLC | 0 | $0 | 0.00% | −247−100.0% | Sold out |
| Wells Fargo & Company | 0 | $0 | 0.00% | −19−100.0% | Sold out |